Mirtazapine Treatment for Comorbid Anxiety/Depressive Disorders in Young Subjects with Attention-Deficit Hyperactivity Disorder: Case Series

Basit Öğe Kaydı
dc.authoridCoskun, Murat/0000-0002-4808-5870
dc.authorwosidCoskun, Murat/A-1377-2017
dc.contributor.authorCoskun, Murat
dc.contributor.authorAhmetoglu, Emine
dc.contributor.authorOzturk, Mucahit
dc.date.accessioned2024-06-12T10:52:11Z
dc.date.available2024-06-12T10:52:11Z
dc.date.issued2010
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: To investigate the efficacy and tolerability of mirtazapine combination with methylphenidate in young subjects with diagnosis of attention deficit hyperactivity disorder (ADHD) and comorbid anxiety or depressive disorders. Method: Subjects with DSM-IV diagnosis of ADHD and comorbid anxiety or depressive disorders were added mirtazapine 7.5 or 15 mg/day initially to treat anxiety or depressive disorders as well as to counteract or avoid methylphenidate or SSRIs related side effects. Improvement in target symptoms were assessed using relevant scales and the Clinical Global Impression-improvement (CGI-1) scale. Results: Subjects were four boys and three girls (11.85 +/- 2.91 years). Duration of methylphenidate and mirtazapine treatment was 14.28 +/- 9.41 and 3.71 0.95 months respectively. Final dose of mirtaza pine was 16 +/- 2.64 mg/day. All subjects showed moderate to very much improvement in sleep and three subjects showed much improvement in appetite problems on CGI-I scale. Six subjects showed mild to very much improvement in anxiety disorders /symptoms and one subject showed much improvement in depression on CGI-I scale. Mirtazapine was generally tolerated well. Most frequently reported side effects were increased appetite (n=5), weight gain (n=4; 1000-4000 gm; 1357.14 +/- 1546.88 gm); day time sedation (n=4) and irritability (n=2). Conclusions: Young subjects with diagnosis of ADHD and comorbid anxiety or depressive disorders may benefit from mirtazapine addition particularly in the presence of methylphenidate or SSRIs related sleep and/or appetite problems.en_US
dc.identifier.doi10.1080/10177833.2010.11790666
dc.identifier.endpage251en_US
dc.identifier.issn1017-7833
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-77957160333en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage246en_US
dc.identifier.urihttps://doi.org/10.1080/10177833.2010.11790666
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18614
dc.identifier.volume20en_US
dc.identifier.wosWOS:000209021000008en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherKure Iletisim Grubu A Sen_US
dc.relation.ispartofKlinik Psikofarmakoloji Bulteni-Bulletin Of Clinical Psychopharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnxietyen_US
dc.subjectADHDen_US
dc.subjectDepressionen_US
dc.subjectComorbidityen_US
dc.subjectMirtazapineen_US
dc.subjectTreatmenten_US
dc.subjectDeficit/Hyperactivity Disorderen_US
dc.subjectOpen-Labelen_US
dc.subjectPsychiatric Comorbidityen_US
dc.subjectSleep Problemsen_US
dc.subjectChildrenen_US
dc.subjectAnxietyen_US
dc.subjectAdolescentsen_US
dc.subjectAtomoxetineen_US
dc.subjectDepressionen_US
dc.subjectFluoxetineen_US
dc.titleMirtazapine Treatment for Comorbid Anxiety/Depressive Disorders in Young Subjects with Attention-Deficit Hyperactivity Disorder: Case Seriesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu